Effect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trial

Simple item page
AuthorMaryam Chamanien
AuthorSaeid Shahrabien
AuthorAli Malmiren
AuthorFereshteh Hassanzadehen
Issued Date2022-01-31en
AbstractBackground: Preeclampsia (PE) is a disease characterized by abnormalities in the placenta and endothelial cells. The pathogenesis is not fully understood; however, aspirin prescription can be effective to treat the disease and prevent fetal developmental disorders. Methods: This study was performed as a clinical trial in Shahid Akbrabadi Hospital in Tehran city. Eighty patients participated in two groups (n = 40). The first group of patients received the dose of 80 mg, and the second group received the dose of 160 mg aspirin. Then, the fetal-maternal and treatment process complications were examined in the patients. Results: The results showed that the incidence of fetal-maternal complications, including intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD) was lower in patients treated with 160 mg aspirin than in the other group, but this difference was not statistically significant (P-value > 0.05). Aspirin complications such as bleeding were more in the second group than in the first one (P-value < 0.05). Conclusions: Although the increasing dose of aspirin reduces fetal-maternal complications in PE patients, the problems such as aspirin-induced bleeding should be considered.en
DOIhttps://doi.org/10.5812/jjcdc.114112en
KeywordAspirinen
KeywordPreeclampsiaen
KeywordFetusen
KeywordMotheren
KeywordComplicationen
PublisherBrieflandsen
TitleEffect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trialen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
jjcdc-11-1-114112.pdf
Size:
112.99 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Jundishapur Journal of Chronic Disease Care